Mccannbowman7863

26%), 83 (34.87%) and 184 (77.31%) patients, respectively; more frequently amongst patients with moderate/severe disease or mortality. Areas under receiver operating characteristic curves and 95% confidence intervals for serum C-reactive protein, ferritin and LDH were 0.909 (0.854-0.964), 0.915 (0.835-0.995) and 0.863 (0.785-0.942), respectively. C-reactive protein ≥45.5 mg/L had sensitivity 86.36% and specificity 88.89%; serum ferritin ≥723 ng/ml had sensitivity 95.45% and specificity 86.57%, and lactate dehydrogenase ≥428.5 U/L had sensitivity 90.91% and specificity 80.56% for predicting mortality.

Levels of the three inflammatory markers at admission can predict mortality in COVID-19 infection. Key Words Coronavirus, Inflammation, Mortality, Outcome, Pakistan.

Levels of the three inflammatory markers at admission can predict mortality in COVID-19 infection. Key Words Coronavirus, Inflammation, Mortality, Outcome, Pakistan.

To assess and identify the risk of prolonged QT about hydroxychloroquine (HQ) and azithromycin (AZ) used in the treatment of patients with COVID-19.

Cohort study.

Kartal Dr. Lütfi Kırdar City Hospital, İstanbul, Turkey, from March to May 2020.

One hundred and forty-four patients with the diagnosis of COVID-19, confirmed by Rt-PCR (reverse transcription-polymerase chain reaction), were restrospectively reviewed. Patients who were hospitalised, received HQ or HQ plus AZ treatment, had a baseline electrocardiogram (ECG), and had at least one ECG after treatment were included in the study. Patients with missing data were excluded.

Fifty-one (35.4%) patients were given hydroxychloroquine monoterapy (HQ), 93 (64.6%) were given hydroxychloroquine plus azithromycin (HA), and 70 (48.6%) were women. Pre-treatment mean QTc measurements were calculated as 410.61 ± 29.44 milliseconds (ms) for HQ group and 412.02 ± 25.37 ms for HA group, while the mean values of post-treatment QTc measurements were calculated as

To evaluate the laboratory confirmed COVID-19 pneumonia and correlate the findings obtained by thorax ultrasound (USG) and thorax computed tomography (CT).

Observational study.

Departments of Infection Disease, Internal Medicine and Radiology, Sakarya Training and Research Hospital, Sakarya, Turkey, between March and May 2020.

This study was consisted of 100 adult patients having rRT-PCR positive COVID-19 pneumonia diagnossed by thorax CT. The clinical features, thorax USG and CT findings of these patients were recorded and expressed. USG and thorax CT findings were scored using a method described before. Continuous variables were expressed as mean (±SD) values. The Kolmogorov-Smirnov test was used for the normal distribution test, and continuous variables were compared using the Mann-Whitney U test. USG and CT performed at time of admission to the hospital. Descriptive statistics were conducted based on the structures of variable.

A total of 100 patients (54 men and 46 women; mean age, 59.88±13.03 years; range, 28-91years) with COVID-19 pneumonia were evaluated. CC-99677 manufacturer Involvement areas on the lower posterior of the right side were detected as 70% by ultrasound and 74% by CT. Positively correlation was detected in lung scans assessed by USG and CT (p<0.001, r=0.705).

Ultrasound has several advantages including no ionizing radiation exposure for health care workers, being a safe, fast and non-invasive diagnostic technique with bedside usage. Hence, ultrasound is an efficient alternative to diagnosis and monitor of patients with COVID-19 pneumonia. Key Words COVID-19, Lung ultrasound, Pneumonia, RRT-PCR.

Ultrasound has several advantages including no ionizing radiation exposure for health care workers, being a safe, fast and non-invasive diagnostic technique with bedside usage. Hence, ultrasound is an efficient alternative to diagnosis and monitor of patients with COVID-19 pneumonia. Key Words COVID-19, Lung ultrasound, Pneumonia, RRT-PCR.

Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) has been accepted as a reliable tool in diagnosing and staging intra-abdominal tumors. In this study, we aimed to investigate the performance of EUS-FNA in the evaluation of liver masses and its impact on patient management and procedure-related complications retrospectively.

Data of patients who underwent EUS-FNA biopsies due to liver masses between November 2017 and July 2018 were retrieved retrospectively. Biopsies were performed using 22-G needles. The demographics, EUS-FNA results, sensitivity and specificity of the procedure, negative predictive value, positive predictive value, and specimen sufficiency rates were assessed.

A total of 25 patients (10 females) were included in the study. The mean age was 62.73±15.2 years. The mean size of the masses was 34.50±16.04 mm. The technical success rate was 88%. During the EUS-FNA procedure, each patient had only one pass with 94.45% of aspirate sufficiency rate and 86.3% of biopsy sufficiency rate. The diagnostic accuracy rate was 86.3%. There were no complications.

For the evaluation of liver masses, EUS-FNA using a 22-G needle with even one pass had high aspiration and biopsy success rates accompanied with high diagnostic accuracy rates.

For the evaluation of liver masses, EUS-FNA using a 22-G needle with even one pass had high aspiration and biopsy success rates accompanied with high diagnostic accuracy rates.

To investigate telemedicine adoption, emergency room avoidance, and related characteristics of patients with chronic obstructive pulmonary disease (COPD) with and without exacerbations since the COVID-19 pandemic began.

We conducted the second of a series of online surveys via SurveyMonkey.com of people with COPD between May 1, 2020 and May 31, 2020. Frequency, percent, and Fisher's exact test (two-sided) were calculated using SPSS version 26.

More than half of respondents (157, 64%), indicated that they started using telemedicine in 2020. Forty-seven percent of respondents had at least one exacerbation since January 1, 2020. Respondents who had at least one exacerbation in 2020 were more likely to start using telemedicine in 2020 than respondents who did not report any exacerbation in 2020 (75.7% versus 54.3%, p < 0.001). Respondents reporting a 2020 exacerbation indicated significantly higher avoidance of emergency healthcare since the pandemic began (27.8%) as compared to those who did not have an exacerbation in 2020 (10.